高级检索
当前位置: 首页 > 详情页

Effects of Betulinic Acid Derivative on Lung Inflammation in a Mouse Model of Chronic Obstructive Pulmonary Disease Induced by Particulate Matter 2.5(Open Access)

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 预警期刊

机构: [1]Department of Respiratory and Critical Care Medicine, First People’s Hospital of Yunnan Province, Kunming, Yunnan, China
出处:
ISSN:

关键词: Anti-Inflammatory Agents Diterpenes Particulate Matter Pulmonary Disease Chronic Obstructive

摘要:
Background: Chronic obstructive pulmonary disease (COPD) is mainly induced by the increased content of particulate matter 2.5 (PM2.5) in the atmosphere. This study aimed to evaluate the effects of betulinic acid derivative on lung inflammation in a mouse model of chronic obstructive pulmonary disease induced by particulate matter 2.5. Material/Methods: The mice were given a PM2.5 (25 μl) suspension for 7 days by the intranasal route to establish a COPD model. The content of TNF-a and IL-6 in the BALF samples was measured by commercially available ELISA kits. Results: The PM2.5-induced higher LDH and ACP levels were significantly alleviated in mouse lung tissues by treatment with betulinic acid derivative. Treatment with betulinic acid derivative also suppressed PM2.5-induced increase in AKP and ALB levels in mouse lung tissues. Betulinic acid derivative reversed PM2.5-mediated suppression of SOD activity and elevation of NOS level in mouse BALF. Moreover, the PM2.5-induced excessive NO and MDA levels in mouse BALF were significantly reduced (P<0.05) by treatment with betulinic acid derivative. Treatment with betulinic acid derivative improved TNF-a and IL-6 levels in BALF induced by PM2.5 exposure. Betulinic acid derivative inhibited PM2.5-induced acute inflammatory exudate, alveolar septae damage, and inflammatory cell infiltration in lungs of mice. Conclusions: In the mouse model of PM2.5-induced COPD, betulinic acid derivative reduced the degree of lung inflammation and downregulated inflammatory mediators. These findings support the need for further in vivo studies and clinical evaluation of betulinic acid derivative in patients with COPD. © Med Sci Monit, 2020

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2020]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Department of Respiratory and Critical Care Medicine, First People’s Hospital of Yunnan Province, Kunming, Yunnan, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82493 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号